Main Article Content
Abstract
This review discusses the definition and types of biomarkers. It also reviews the potential use of biomarkers in diagnosing, Treating, Predecting the course of various diseases such as cardiovascular, Infectious, Cancer. The current review focuses on biomarkers for CVD, Infectious, Cancer and the procedures that should be consider to establish the comprehensive nature of the expression of biomarkers for cardiovascular diseases. It also discusses how biomarkers can help with treatment decisions and monitoring disease progression.
Keywords
Article Details
References
- 1. Naylor S. (2003) Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 3:525-29.
- 2. Carser JE, Quinn JE, Michie CO, O'Brien EJ, McCluggage WG, Maxwell P, Lamers E, Lioe TF, Williams AR, Kennedy RD, Gourley C, Harkin DP. (2011) BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol 123(3):492-8.
- 3. Sahu P, Pinkalwar N, Dubey RD, Paroha S, Chatterjee S, Chatterjee T. (2011) Biomarkers: an emerging tool for diagnosis of a disease and drug development.
- 4. Mayeux R. (2004) Biomarkers: Potential uses and limitations. J Am Soc Exp Neuro Therap 1:182-88.
- 5. Wallis R. S., Maeurer M., Mwaba P., et alTuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. The Lancet Infectious Diseases. 2016;16(4):e34-e46. doi: 10.1016/S1473-3099(16)00070-0.
- 6. Morency-Potvin P., Schwartz D. N., Weinstein R. A. Antimicrobial stewardship: how the microbiology laboratory can right the ship.Clinical Microbiology Reviews. 2017;30(1):381-407. doi: 10.1128/CMR.00066-16.
- 7. Spellberg B., Bartlett J., Wunderink R., Gilbert D. N. Novel approaches are needed to develop tomorrow's antibacterial therapies. American Journal of Respiratory and Critical Care Medicine. 2015;191(2):135-140. doi: 10.1164/rccm.201410-18940E.
References
1. Naylor S. (2003) Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 3:525-29.
2. Carser JE, Quinn JE, Michie CO, O'Brien EJ, McCluggage WG, Maxwell P, Lamers E, Lioe TF, Williams AR, Kennedy RD, Gourley C, Harkin DP. (2011) BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol 123(3):492-8.
3. Sahu P, Pinkalwar N, Dubey RD, Paroha S, Chatterjee S, Chatterjee T. (2011) Biomarkers: an emerging tool for diagnosis of a disease and drug development.
4. Mayeux R. (2004) Biomarkers: Potential uses and limitations. J Am Soc Exp Neuro Therap 1:182-88.
5. Wallis R. S., Maeurer M., Mwaba P., et alTuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. The Lancet Infectious Diseases. 2016;16(4):e34-e46. doi: 10.1016/S1473-3099(16)00070-0.
6. Morency-Potvin P., Schwartz D. N., Weinstein R. A. Antimicrobial stewardship: how the microbiology laboratory can right the ship.Clinical Microbiology Reviews. 2017;30(1):381-407. doi: 10.1128/CMR.00066-16.
7. Spellberg B., Bartlett J., Wunderink R., Gilbert D. N. Novel approaches are needed to develop tomorrow's antibacterial therapies. American Journal of Respiratory and Critical Care Medicine. 2015;191(2):135-140. doi: 10.1164/rccm.201410-18940E.